Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)
Background. Kinase domain mutations of BCR-ABL gene is the most common cause of tyrosine kinase inhibitor resistance. Aim. To present the data on prognostic value of BCR-ABL mutation burden in Russian patients over the last 10 years. Materials & Methods. The study included 1885 chronic mye...
Main Authors: | VV Tikhonova, MA Isakov, VA Misyurin, YuP Finashutina, LA Kesaeva, NA Lyzhko, IN Soldatova, NN Kasatkina, EN Misyurina, AV Misyurin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Practical Medicine Publishing House
2018-07-01
|
Series: | Kliničeskaâ onkogematologiâ |
Subjects: | |
Online Access: | http://bloodjournal.ru/wp-content/uploads/2018/06/3-2.pdf |
Similar Items
-
Expression of the BCR-ABL1 Gene in Patients with Chronic Myeloproliferative Diseases with Signs of Progression
by: LA Kesaeva, et al.
Published: (2018-10-01) -
Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica Atypical BCR-ABL transcript in a patient with chronic myeloid leukemia
by: Ana María Amor Vigil, et al.
Published: (2011-09-01) -
Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
by: Maria Helena de Almeida, et al.
Published: (2014-01-01) -
Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
by: Asako Takeuchi, et al.
Published: (2021-01-01) -
p210BCR‐ABL1‐ Chronic myeloid leukemia presents with monocytosis
by: Xiaofei Wang, et al.
Published: (2020-05-01)